菌体尾酒通过重塑肠道微生物群和减少促炎细胞因子来缓解2型糖尿病
Jianming Ye1, Qiang Meng1, Kezhu Jin1
1College of Food Science and Technology, Northwest University, Xi'an, 710069, Shaanxi, China.
Applied microbiology and biotechnology
|December 30, 2023
概括
一种菌体尾酒 (MS2-P22) 在2型糖尿病 (T2D) 小鼠中改善了肠道微生物群平衡和肠道屏障功能. 这种干预增加了有益细菌和短链脂肪酸,为T2D提供了新的饮食策略.
科学领域:
- 微生物学 微生物学
- 代谢学 代谢学 代谢学
- 免疫学 免疫学 免疫学
背景情况:
- 2型糖尿病 (T2D) 与肠道微生物群不平衡有关.
- 像MS2和P22这样的菌体可以选择性地调节肠道微生物群.
- 对T2D相关微生物群的菌体影响的系统分析是有限的.
研究的目的:
- 研究MS2-P22菌体尾酒对T2D肠道微生物群和宿主新陈代谢的级联影响.
- 为了确定肠道细菌,代谢物和T2D指标之间的相关性.
- 评估菌体尾酒对T2D的治疗潜力.
主要方法:
- 多原子分析 (微生物学,代谢学).
- 在糖尿病C57BL/6小鼠中MS2-P22菌体尾酒的裂变 (由HFD和STZ引起).
- 评估微生物组成,代谢物概况和宿主炎症标志物.
主要成果:
- 在T2D小鼠中,MS2-P22菌体尾酒减弱了肠道失调.
- 增加SCFA产生细菌 (例如,布劳蒂亚,罗姆布茨亚) 和SCFA的丰度.
- 减少机会性病原体和降低了促炎性细胞因子和LPS的水平,改善了肠道屏障功能.
结论:
- 菌体尾酒可以重塑肠道微生物组,并改善T2D的肠道平衡.
- 特定的细菌转移和SCFA生产是菌体治疗的关键机制.
- 基于菌体的干预措施显示出作为一种新的饮食策略来管理T2D的承诺.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Lytic Cycle of Bacteriophages
70.7K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.7K
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
Chronic Pancreatitis II: Collaborative Care
92
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
92
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166


